Alk­er­mes, Te­va set­tle patent suit around opi­oid-block­er Viv­it­rol, paving way for gener­ics af­ter three-year fight

Alk­er­mes has agreed to give Te­va a li­cense to make a gener­ic ver­sion of its opi­oid-block­ing drug Viv­it­rol in or­der to stop patent lit­i­ga­tion that be­gan in 2020, the com­pa­ny an­nounced Wednes­day.

Un­der the set­tle­ment, Te­va can start mak­ing a gener­ic ver­sion of the in­jectable start­ing on Jan. 15, 2027, or pos­si­bly ear­li­er un­der “cus­tom­ary cir­cum­stances.” Alk­er­mes’ patent for the drug would have ex­pired in 2029.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER